Lauren Maslin

Senior Associate, Portfolio Strategy

2024 - Current

Senior Associate

2024 - 2024

Associate

2022 - 2024

Senior Analyst

2021 - 2022

• Promoted from part-time analyst (November 2019-August 2021) • Leads scientific and investment diligence on biotech companies with a focus in the oncology and immuno-oncology space • Authors multiple investment and declination memos highlighting a holistic analysis of the prospective companies; including technical, regulatory, market, financial and intellectual property analysis • Entrusted to represent Catalio at board meetings for several portfolio companies

Regulatory Postdoctoral Fellow

2021 - 2021

•Assisted in the submission of Investigational New Drug (IND) applications for oncology-related clinical trials •Provided regulatory guidance to IND sponsors, clinical investigators and clinical staff for investigator initiated clinical trials •Reviewed clinical trial databases to assess clinical data quality and accuracy

PhD Candidate

2016 - 2021

• Developed a novel approach to investigate the systemic vs tumor effects of MEK inhibition • Investigating novel drug combinations to maximize the positive immunomodulatory effects of MEK inhibition in RAS driven tumors

Cancer Research Intern

2015 - 2015

• Investigated the collaborative role of mutations in JAK2 and ASXL1 loss in Myeloproliferative Disorders • Selected from a pool of over 800 applicants for GSK Summer Undergraduate Research Program • 1 of 3 interns named 2015 Rubin and Sarah Shaps scholar

Cancer Research Intern

2014 - 2014

• Investigated if the relapse-specific mutations in NT5CIB found in patients with acute lymphoblastic leukemia were leading to resistance to nucleoside analogue chemotherapies • Selected from a pool of over 1,000 applicants for the NYU Summer Undergraduate Research Program